Using a Revenue DCF model with operating margin convergence from -7742.2% to a target of 13.4% over 5 years, discounted at a WACC of 12.7%, BioXcel Therapeutics, Inc. (BTAI) has an intrinsic value of $233.90 per share (range: $163.58 – $340.95).
Using a Revenue DCF model with operating margin convergence from -7742.2% to a target of 13.4% over 5 years, discounted at a WACC of 12.7%, BioXcel Therapeutics, Inc. (BTAI) has an intrinsic value of $1,546.69 per share (range: $1,162.66 – $2,145.44).
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.